Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexmedetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 11/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 11/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 11/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 7/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmedetomidine SCHEMBL30282088 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL2202289 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL2203716 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29363193 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL787407 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL29945090 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL31048740 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL26433 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29546835 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL28305816 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12501899-B2 | Mite infestation treatment | VETO-PHARMA (FR) | 2025-12-23 | — | — | US | disclosed |
| CN-115616104-B | Dextromethorphan hydrochloride injection of medetomidine method for detecting liquid enantiomer | 山西远扬医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118652165-A | Chiral binaphthyl macrocyclic arene, derivative, and synthetic method and application thereof | 天津师范大学 | 2024-09-17 | — | — | CN | disclosed |
| CN-115003159-B | Mite infestation treatment | 伟途制药公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114983934-B | Dexmedetomidine hydrochloride injection | 南京正科医药股份有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20230023961-A1 | MITE INFESTATION TREATMENT | VETO-PHARMA (FR) | 2023-01-26 | — | — | US | disclosed |
| CN-115616104-A | Method for detecting enantiomer of dexmedetomidine hydrochloride injection | 山西远扬医药科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-4072293-A1 | MITE INFESTATION TREATMENT | Veto-Pharma (FR) | 2022-10-19 | — | — | EP | disclosed |
| CN-114983934-A | Dexmedetomidine hydrochloride injection | 南京正科医药股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003159-A | Mite infestation treatment | 伟途制药公司 | 2022-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023961-A1 | MITE INFESTATION TREATMENT | RHOA, NPEPPS, TUBA3E | ADRA2A 3402/4885ADRA2B 3269/4885ADRA2C 2479/4885 |
| US-12501899-B2 | Mite infestation treatment | RHOA, NPEPPS, TUBA3E | ADRA2A 3402/4885ADRA2B 3269/4885ADRA2C 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.